# Combinatietherapie lipidenverlagers biedt superieure plaque-stabilisatie versus monotherapie

*geplaatst 2026-11-22 · Cholesterol · American heart journal plus : cardiology research and practice · doi 10.1016/j.ahjo.2026.101001 · https://hartvaat.nl/2026/12/01/combinatietherapie-lipidenverlagers-biedt-superieure-plaque-stabilisatie-versus-/*

Een netwerkmeta-analyse van 78 RCTs vergeleek de effecten van statines, ezetimibe, PCSK9-remmers en combinaties op beeldvormende markers van plaque-instabiliteit (vezelcapseldikte, atheroomvolume en CIMT). Combinatietherapieën toonden een superieur effect op plaque-stabilisatie en regressie vergeleken met monotherapieën, waarbij elke statine een uniek profiel vertoonde zonder één overkoepelende winnaar. De bevindingen ondersteunen een gepersonaliseerde keuze van lipidenverlagende strategieën op basis van plaque-eigenschappen, comorbiditeit en praktische overwegingen, hoewel lange termijn klinische uitkomsten nog bevestigd moeten worden.

## English: Systematic review and network meta-analysis: Comparison and selection of lipid-lowering strategies for improving atherosclerotic plaque vulnerability.

A network meta-analysis of 78 RCTs compared the effects of statins, ezetimibe, PCSK9 inhibitors, and their combinations on imaging markers of plaque vulnerability (fibrous cap thickness, percent atheroma volume, and CIMT). Combination regimens demonstrated superior plaque stabilization and regression compared to monotherapies, with individual statins showing distinct efficacy profiles across the different imaging endpoints. These findings support a personalized approach to lipid-lowering therapy based on plaque characteristics, comorbidities, and practical considerations, though long-term hard clinical outcomes require further validation.

## Abstract (original, from the publication)

BACKGROUND: Cholesterol is a causal pathogenic risk factor for atherosclerosis. Effective management of low-density lipoprotein cholesterol (LDL-C) stabilizes or regresses plaques and reduces cardiovascular events. Fibrous cap thickness (FCT), percent atheroma volume (PAV), and carotid intima-media thickness (CIMT) are core imaging markers for plaque evaluation, yet head-to-head comparisons of different lipid-lowering regimens on these endpoints are lacking. OBJECTIVE: To systematically compare, via network meta-analysis (NMA), the efficacy of statin monotherapies, ezetimibe monotherapy, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor monotherapy, and their combinations on FCT, PAV, and CIMT. METHODS: We searched PubMed, Web of Science, Embase, and Cochrane for randomized controlled trials (RCTs) published up to October 4, 2026. Eligible interventions included seven statins, ezetimibe, PCSK9 inhibitors, and other agents. Primary endpoints were FCT and PAV. Secondary endpoint was CIMT. Standardized procedures were used for screening, data extraction, and NMA. RESULTS: A total of 78 RCTs were included. Significant heterogeneity was observed across regimens. Combination therapies showed superior comprehensive plaque-modulating effects versus monotherapies. Each statin exhibited unique strengths across the three endpoints; no single agent performed best on all markers. CONCLUSIONS: Combination lipid-lowering provides stronger plaque stabilization and regression, while statin monotherapies offer definite but heterogeneous benefits, supporting personalized choices based on plaque characteristics, comorbidities, financial constraints, and adherence. This NMA yields high-reliability evidence for stratified clinical decisions. Extended long-term trials are needed to confirm durable benefits.This systematic review was conducted in strict accordance with the PRISMA 2020 guidelines.

Auteurs: Yanyi Sun, Min Li, Jingwei Ni, Zhenyue Chen

---
Bron: American heart journal plus : cardiology research and practice, https://doi.org/10.1016/j.ahjo.2026.101001. Bijgewerkt 2026-11-15T02:20:35Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.
